Thrombotic risk according to SERPINC1 genotype in a large cohort of subjects with antithrombin inherited deficiency

Summary

Inherited quantitative (type I) or qualitative (type II) antithrombin deficiency (ATD) due to mutations in the SERPINC1 gene is a well-known risk factor for venous thromboembolism. ATD may also increase risk for arterial thrombosis. Few studies have investigated risk for thrombosis according to mutations. We addressed this topic in a large retrospective cohort study of 540 heterozygous carriers of SERPINC1 mutations and compared risk for first venous or arterial thrombosis associated with carrying of different type II or type I mutations. No clear difference in risk for first venous thrombotic event was observed among type I (missense or null), type IIRS or type IIPE mutation carriers except for a few variants that displayed lower risk [all events, adjusted relative risk: Cambridge II: 0.42 (95%CI 0.25–0.70), Dublin: 0.35 (95%CI 0.13–0.99)]. IIHBS mutation carrying was associated with a clearly lower risk than type I mutation carrying [0.28 (95%CI 0.20–0.40)]. These differences in risk were observed for both all venous thrombotic events and pulmonary embolism associated with deep venous thrombosis. The HBS group was also heterogeneous, with AT Budapest 3 carriers displaying a non-significantly different risk [0.61 (95%CI 0.31–1.20)] compared to type I mutation carriers. We also studied risk for arterial thrombosis and found no significant influence of mutation type. Altogether, our findings suggest a place for SERPINC1 genotyping in the diagnosis of ATD.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Coagulation inhibitor - antithrombin - SERPINC1 - thrombophilia - thrombosis

• References

• 1 Harper PL, Carrell RW. The serpins. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EG, editors. Haemostasis and Thrombosis New York: Churchill-Livingstone; 1994: 641-653.
• 2 Patnak NM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008; 14: 1229-1239.
• 3 Lane DA, Bayston T, Olds RJ. et al. Antithrombin mutation Database: 2nd (1997) Update. Thromb Haemost 1997; 77: 197-211.
• 4 Di Mino MND, Ambrosino P, Ageno W. et al. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2015; 135: 923-932.
• 5 Finazzi G, Caccia R, Barbui T. Different prevalences of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58: 1094.
• 6 Luxembourg B, Pavlova A, Geisen C. et al. Impact of the type of SERPINC1 mutation and subtype of antithrombin deficiency on the thrombotic phenotype on hereditary antithrombin deficiency. Thromb Haemost 2014; 111: 249-257.
• 7 Puurunen M, Salo P, Engelbarth S. et al. Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture. J Thromb Haemost 2013; 11: 1844-1849.
• 8 Gindele R, Olah Z, Iloncza P. et al. Founder effect is responsible for the p.Leu131Phe heparin-binding-site antithrombin mutation common in Hungary: phenotype analysis in a large cohort. J Thromb Haemost 2016; 14: 704-715.
• 9 Corral J, Hernandez-Espinosa D, Soria JM. et al. Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. Blood 2007; 109: 4258-4263.
• 10 Navarro-Fernandez J, De la Morena-Barrio ME, Padilla J. et al. Antithrombin Dublin (p.Val30Glu): a relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency. Thromb Haemost 2016; 116: 146-154.
• 11 Soare AM, Popa C. Deficiencies of protein C, S and Antithrombin and Activated Protein C resistance – their involvement in the occurrence of arterial thrombosis. J Med Life 2010; 3: 412-415.
• 12 Roldan V, Ordonez A, Marin F. et al. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Haemost 2009; 101: 483-486.
• 13 Kuhle S, Lane DA, Jochmanns K. et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost 2001; 86: 1007-1011.
• 14 Orlando C, Heylen O, Lissens W, Jochmans K. Antithrombin heparin bindig site deficiency: a challenging diagnosis of a not so benign thrombophilia. Thromb Res 2015; 135: 1179-1185.
• 15 Picard V, Dautzenberg MD, Villoutreix BO. et al. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerisation in vivo associated with severe childhood thrombosis. Blood 2003; 102: 919-925.
• 16 Ng p PC, Henikoff S. SIFT: Predicting amino-acid changes that affect protein function. Nucleic Acids Res 2003; 30: 3812-3814.
• 17 Adzhubei IA, Schmidt S, Peshkin L. et al. A method and server for predicting damaging missense mutations. Nature Methods 2010; 7: 248-249.
• 18 Houdayer C. In silico prediction of splice-affecting nucleotide variants. In silico tools for gene discovery. Methods Mol Biol 2011; 760: 269-281.
• 19 Luxembourg B, D’Souza M, Körber S. et al. Prediction of the pathogenicity of anti-thrombin sequence variations by in silico methods. Thromb Res 2015; 135: 404-409.
• 20 Alhenc-Gelas M, Canonico M, Picard V. Influence of natural SERPINC1 mutations on ex vivo thrombin generation. J Thromb Haemost 2010; 8: 2718-2726.
• 21 Jin L, Abrahams JP, Skinner R. et al. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14638.
• 22 Beauchamp NJ, Pike RN, Daly M, Butler R. et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis and heparin activation. Blood 1998; 92: 2696-2706.
• 23 Picard V, Dautzenberg MD, Villoutreix B. et al. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerisation in vivo associated with severe childhood thrombosis. Blood 2003; 102: 919-925.
• 24 Lane DA, Olds RJ, Conard J. et al. Pleiotropic effects of antithrombin strand 1C substitution mutations. J Clin Invest 1992; 90: 2422-2433.
• 25 Ni H, Blajchman MA, Ananthanarayanan VS. et al. Mutation of any site of N-glycosylation accelerates the in vivo clearance of recombinant rabbit anti-thrombin. Thromb Res 2000; 99: 407-415.
• 26 Picard V, Chen JM, Tardy B. et al. Detection and characterisation of large SERPINC1 deletions in type I inherited antithrombin deficiency. Hum Genet 2010; 127: 45-53.
• 27 Picard V, Présot I, Scarabin PY. et al. Antithrombin Cambridge II (A384S): prevalence in patients of the Paris Thrombosis Study (PATHROS). Blood 2007; 110: 2777-2778.
• 28 Sanchez C, Alessi MC, Saut N. et al. Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. J Thromb Haemost 2008; 6: 1975-1977.